Revisiting the Boundaries of GDMT Optimization: Beyond Adverse Effects and Into the Future of Personalized Heart Failure Care.
作者信息
Rehman Ateeq Ur, Rayyan Syed Muhammad, Khan Areeba
机构信息
Ayub Medical College, Abbottabad, Pakistan.
出版信息
Clin Cardiol. 2025 Jul;48(7):e70187. doi: 10.1002/clc.70187.
Abstract
摘要
相似文献
1
Revisiting the Boundaries of GDMT Optimization: Beyond Adverse Effects and Into the Future of Personalized Heart Failure Care.重新审视指南-directed药物治疗（GDMT）优化的边界：超越不良反应，迈向个性化心力衰竭护理的未来。
Clin Cardiol. 2025 Jul;48(7):e70187. doi: 10.1002/clc.70187.
2
Impact of Medication Dose Optimization on Heart Failure Outcomes in African-American Female Patients: A Safety-Net Hospital Experience.药物剂量优化对非裔美国女性心力衰竭患者预后的影响：一家安全网医院的经验
Cureus. 2025 Jul 7;17(7):e87443. doi: 10.7759/cureus.87443. eCollection 2025 Jul.
3
Tolerability and Adverse Effects in a Specialized Heart Failure Guideline-Directed Medical Therapy Optimization Program.一项专门的心力衰竭指南指导下的药物治疗优化计划中的耐受性和不良反应
Clin Cardiol. 2025 Jul;48(7):e70179. doi: 10.1002/clc.70179.
4
Rationale, design, and baseline characteristics of the virtual care to improve heart failure outcomes (VITAL-HF) trial.虚拟护理改善心力衰竭结局（VITAL-HF）试验的原理、设计和基线特征
Am Heart J. 2025 Dec;290:46-57. doi: 10.1016/j.ahj.2025.06.001. Epub 2025 Jun 3.
5
Early Initiation of Guideline-Directed Medical Therapy Improves Outcomes in Heart Failure with Reduced Ejection Fraction Patients without Significant Risk of Nephrotoxicity.早期启动指南导向的药物治疗可改善射血分数降低的心力衰竭患者的预后，且这些患者无显著肾毒性风险。
Acta Cardiol Sin. 2025 Jul;41(4):510-520. doi: 10.6515/ACS.202507_41(4).20250324A.
6
The Effect of Using a Remote Patient Management Platform in Optimizing Guideline-Directed Medical Therapy in Heart Failure Patients: A Randomized Controlled Trial.远程患者管理平台对心力衰竭患者优化指南导向药物治疗的效果：一项随机对照试验。
JACC Heart Fail. 2024 Apr;12(4):678-690. doi: 10.1016/j.jchf.2024.02.008.
7
Pharmacist-led guideline-directed medical therapy in heart failure: impact analysis in primary care.由药剂师主导的心力衰竭指南指导药物治疗：基层医疗中的影响分析
BMJ Open Qual. 2025 Sep 1;14(3):e003401. doi: 10.1136/bmjoq-2025-003401.
8
Guideline-Directed Medical Therapy Use in the STRONG-HF Trial.STRONG-HF试验中基于指南的药物治疗应用
Circ Heart Fail. 2025 Jul 3:e012716. doi: 10.1161/CIRCHEARTFAILURE.124.012716.
9
In-hospital Utilization and Dose Optimization of Guideline-Directed Medical Therapies among Acute Heart Failure Yemeni Patients.也门急性心力衰竭患者指南指导下药物治疗的院内使用情况及剂量优化
Heart Views. 2025 Jan-Mar;26(1):7-18. doi: 10.4103/heartviews.heartviews_152_24. Epub 2025 Jul 16.
10
Clinical outcomes of patients from older community hospitalized for heart failure in guideline-directed medical therapy era: Insights from the COMPASS-HF registry.在指南指导药物治疗时代老年社区心力衰竭住院患者的临床结局：来自COMPASS-HF注册研究的见解
J Cardiol. 2025 Mar;85(3):257-259. doi: 10.1016/j.jjcc.2024.09.006. Epub 2024 Sep 17.
本文引用的文献
1
Tolerability and Adverse Effects in a Specialized Heart Failure Guideline-Directed Medical Therapy Optimization Program.一项专门的心力衰竭指南指导下的药物治疗优化计划中的耐受性和不良反应
Clin Cardiol. 2025 Jul;48(7):e70179. doi: 10.1002/clc.70179.
2
Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.医师对射血分数降低的心力衰竭患者实施指南指导的药物治疗的看法、态度和策略。一项对 ESC 心力衰竭协会和 ESC 心脏病学实践理事会的调查。
Eur J Heart Fail. 2024 Jun;26(6):1408-1418. doi: 10.1002/ejhf.3214. Epub 2024 Mar 22.
3
Medication-Attributable Adverse Events in Heart Failure Trials.心力衰竭试验中的药物相关不良事件
JACC Heart Fail. 2023 Apr;11(4):425-436. doi: 10.1016/j.jchf.2022.11.026. Epub 2023 Feb 1.
4
Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry.心力衰竭合并射血分数降低的肥胖与非肥胖患者心力衰竭药物治疗的使用情况及其与结局的相关性：来自瑞典心力衰竭注册登记处的数据。
Eur J Heart Fail. 2023 May;25(5):698-710. doi: 10.1002/ejhf.2795. Epub 2023 Mar 6.
5
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.升阶梯治疗急性心力衰竭指南导向的药物治疗的安全性、耐受性和疗效（STRONG-HF）：一项多中心、开放标签、随机试验。
Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
6
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction.在斯库拉和卡律布狄斯之间航行：在射血分数降低的心力衰竭中实施指南指导的药物治疗的挑战和策略。
Eur J Heart Fail. 2021 Dec;23(12):1999-2007. doi: 10.1002/ejhf.2378. Epub 2021 Dec 13.
7
Clinical inertia and medical therapy for heart failure: the unintended harms of 'first, do no harm'.临床惰性与心力衰竭的药物治疗：“首先，不伤害”的意外危害
Eur J Heart Fail. 2021 Aug;23(8):1343-1345. doi: 10.1002/ejhf.2283. Epub 2021 Jul 6.
Zotero 插件